Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease: Real-Life Results
What is known
What this study adds
Table 1: Effect of long-term (8 years) testosterone therapy on testosterone levels and metabolic outcomes.
Testosterone treated group
Total testosterone levels
↑ 283 to 476 ng/dL
(9.8 to 16.5 nmol/L)
↓ 277 to 260 ng/dL
(9.6 to 9 nmol/L)
Body weight (lb)
Waist circumference (in)
↓ 229 to 192, -17.0%
↓42 to 38
↓ 33 to 28
↑ 202 to 204, +1.5%
↑ 42 to 43
↑ 29 to 30
↓103 to 94 mg/dL
↓6.9% to 5.6%
↑from 6.1% to 6.4%
Systolic blood pressure (SBP)
Diastolic blood pressure (DBP)
Rate pressure product
↓151 mmHg to 130 mmHg
↓ 91 mmHg to 74 mmHg
↓61 mmHg to 56 mmHg
↓ 11 751 to 9421
↑ 139.5 mmHg to 140.3 mmHg
↑ 80 mmHg to 81 mmHg
↑ 10 623 to 10 890
Lipid Profile (mg/dL)
↓ 278 to 186
↓ 162 to 104
↑ 54 to 73
↓ 275 to 186
↓ 5.6 to 2.6
↓ 224to 113
↑ 244 to 263
↑ 135 to 155
↑ 50 to 62
↑ 257 to 75
↑ 6.2 to 5.6 (not significant)
↑ 194 to 201
Liver Function Enzymes (U/L)
↓ 40 to 16
↓ 42 to 16
↑ 23 to 40
↑ 27 to 44
Note: All changes are significant unless stated otherwise.
1. Cox, J.L. and K. Pieper, Harnessing the power of real-life data. European Heart Journal Supplements, 2015. 17(suppl_D): p. D9-D14.
2. Stanley, K., Design of randomized controlled trials. Circulation, 2007. 115(9): p. 1164-9.
3. Houle, S., An introduction to the fundamentals of randomized controlled trials in pharmacy research. Can J Hosp Pharm, 2015. 68(1): p. 28-32.
4. Annemans, L., M. Aristides, and M. Kubin. Real-Life Data: A Growing Need. The Official News & Technical Journal of The International Society for Pharmacoeconomics and Outcomes Research. Available at https://www.ispor.org/news/articles/oct07/rld.asp (accessed Febr 12, 2017).
5. Traish, A., et al., Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups. Journal of Cardiovascular Pharmacology and Therapeutics, 2017: p. epub.
6. Saad, F., et al., Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Int J Obes (Lond), 2016. 40(1): p. 162-70.
7. Yassin, A., et al., Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men. Clin Endocrinol (Oxf), 2016. 84(1): p. 107-14.
8. Yassin, A., et al., Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male, 2016. 19(1): p. 64-9.
9. Yassin, A.A., et al., Effects of continuous long-term testosterone therapy (TTh) on anthropometric, endocrine and metabolic parameters for up to 10 years in 115 hypogonadal elderly men: real-life experience from an observational registry study. Andrologia, 2016: p. Jan 14. doi: 10.1111/and.12514. [Epub ahead of print].
10. Yassin, A.A., et al., Effects of continuous long-term testosterone therapy (TTh) on anthropometric, endocrine and metabolic parameters for up to 10 years in 115 hypogonadal elderly men: real-life experience from an observational registry study. Andrologia, 2016. 48(7): p. 793-9.
11. Saad, F., et al., Elderly men over 65 years of age with late-onset hypogonadism benefit as much from testosterone treatment as do younger men. Korean J Urol, 2015. 56(4): p. 310-7.
12. Haider, A., et al., Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study. Vasc Health Risk Manag, 2016. 12: p. 251-61.
13. Francomano, D., et al., Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J Endocrinol Invest, 2014. 37: p. 401-411.
14. Francomano, D., et al., Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology, 2014. 83(1): p. 167-73.
15. Francomano, D., A. Lenzi, and A. Aversa, Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol, 2014. 2014: p. 527470.
16. Haider, A., et al., Progressive Improvement of T-Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years. Int J Endocrinol, 2014. 2014: p. 496948.
17. Haider, A., et al., Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: An observational study. Obes Res Clin Pract, 2014. 8(4): p. e339-49.
18. Haider, A., et al., Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol, 2014. 2014: p. 683515.
19. Haider, A., et al., Incidence of Prostate Cancer in Hypogonadal Men Receiving Testosterone Therapy: Observations from Five Year-median Follow-up of Three Registries. J Urol, 2015. 193(1): p. 80-86.
20. Saad, F., et al., Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring), 2013. 21(10): p. 1975-81.
21. Yassin, A. and G. Doros, Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obes, 2013. 3(3-4): p. 73-83.
22. Yassin, D.J., et al., Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med, 2014. 11(6): p. 1567-76.
23. Permpongkosol, S., et al., Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism. J Sex Med, 2016. 13(8): p. 1199-211.
24. Saad, F., Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease? Diabetes Metab Res Rev, 2012. 28 Suppl 2: p. 52-9.
25. Saad, F., et al., Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev, 2012. 8(2): p. 131-43.
26. Saad, F., et al., Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol, 2011. 165(5): p. 675-85.
27. Saad, F. and L.J. Gooren, The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. J Obes, 2011. 2011.
28. Traish, A., Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return? Investig Clin Urol, 2016. 57(6): p. 384-400.
29. Saad, F., et al., Testosterone Deficiency and Testosterone Treatment in Older Men. Gerontology, 2017. 63(2): p. 144-156.
30. Traish, A.M., et al., Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract, 2014. 68(3): p. 314-29.
31. Vigen, R., et al., Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA, 2013. 310(17): p. 1829-36.
32. Finkle, W.D., et al., Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One, 2014. 9(1): p. e85805.
33. Xu, L., et al., Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med, 2013. 11: p. 108.
34. Basaria, S., et al., Adverse events associated with testosterone administration. N Engl J Med, 2010. 363(2): p. 109-22.
35. Morgentaler, A., et al., Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc, 2015. 90(2): p. 224-51.
36. FDA Citizen Petition Denial Response from FDA CDER to Public Citizen, available at http://www.regulations.gov/#!documentDetail;D=FDA-2014-P-0258-0003, accessed Aug 31, 2014.
37. European Medicines Agency, PRAC review does not confirm increase in heart problems with testosterone medicines - Committee recommends medicines can continue to be given for their authorised uses. Avaliable at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/10/WC500175207.pdf Accessed Dec 14, 2015. 2014.
38. Petrick, A., et al., Utility of Ultrasound, Transaminases, and Visual Inspection to Assess Nonalcoholic Fatty Liver Disease in Bariatric Surgery Patients. Obes Surg, 2015. 25(12): p. 2368-75.
39. Haider, A., et al., Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Exp Clin Endocrinol Diabetes, 2010. 118(3): p. 167-71.
40. Hoyos, C.M., et al., Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol, 2012. 167(4): p. 531-41.
41. Kral, J.G., et al., Body fat topography as an independent predictor of fatty liver. Metabolism, 1993. 42(5): p. 548-51.
42. Mody, A., et al., Relevance of low testosterone to non-alcoholic fatty liver disease. Cardiovasc Endocrinol, 2015. 4(3): p. 83-89.
43. Lazo, M., et al., Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol, 2013. 178(1): p. 38-45.
44. American Diabetes Association, Standards of Medical Care in Diabetes-2017 Abridged for Primary Care Providers. Clin Diabetes, 2017. 35(1): p. 5-26.
45. American Diabetes Association, 2. Classification and Diagnosis of Diabetes. Available at http://care.diabetesjournals.org/content/40/Supplement_1 (accessed February 21, 2017). Diabetes Care, 2017. 40(Supplement 1): p. S11-S24.
46. Safar, M.E., B.I. Levy, and H. Struijker-Boudier, Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation, 2003. 107(22): p. 2864-9.
47. Hamilton, P.K., et al., Arterial stiffness: clinical relevance, measurement and treatment. Clin Sci (Lond), 2007. 113(4): p. 157-70.
48. Safar, M.E., Pulse pressure, arterial stiffness and wave reflections (augmentation index) as cardiovascular risk factors in hypertension. Ther Adv Cardiovasc Dis, 2008. 2(1): p. 13-24.
49. Zhao, L., et al., Brachial pulse pressure and cardiovascular or all-cause mortality in the general population: a meta-analysis of prospective observational studies. J Clin Hypertens (Greenwich), 2014. 16(9): p. 678-85.
50. Benetos, A., et al., Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension, 1998. 32(3): p. 560-4.
51. May, G.A. and F.J. Nagle, Changes in rate-pressure product with physical training of individuals with coronary artery disease. Phys Ther, 1984. 64(9): p. 1361-6.
52. Sembulingam, P., et al., Rate Pressure Product as a Determinant of Physical Fitness in Normal Young Adults. IOSR Journal of Dental and Medical Sciences, 2015. 14(4): p. 8-12.
53. Soundariya, K., V. Deepika, and S.P. Venkatesh, A comparative analysis of rate pressure product between prehypertensives and normotensives and its correlation with body mass index Indian Journal of Clinical Anatomy and Physiology, 2016. 3(4): p. 452-455.
54. Bays, H.E., et al., Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol, 2013. 7(4): p. 304-83.
55. Arsenault, B.J., S.M. Boekholdt, and J.J. Kastelein, Lipid parameters for measuring risk of cardiovascular disease. Nat Rev Cardiol, 2011. 8(4): p. 197-206.
56. Adiels, M., et al., Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol, 2008. 28(7): p. 1225-36.
57. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel, An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report. J Clin Lipidol, 2014. 8(1): p. 29-60.
58. Catapano, A.L., et al., ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis, 2011. 217(1): p. 3-46.
59. Bays, H.E., et al., National Lipid Association Annual Summary of Clinical Lipidology 2016. J Clin Lipidol, 2016. 10(1 Suppl): p. S1-S43.
60. Jellinger, P.S., et al., American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract, 2017.
61. Muraleedharan, V., et al., Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol, 2013. 169(6): p. 725-33.
62. Shores, M.M., et al., Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab, 2012. 97(6): p. 2050-8.
63. Baillargeon, J., et al., Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy. Ann Pharmacother, 2014. 48(9): p. 1138-1144.
64. Eisenberg, M.L., et al., Testosterone therapy and mortality risk. Int J Impot Res, 2015. 27(2): p. 46-8.
65. Tan, R.S., K.R. Cook, and W.G. Reilly, Myocardial Infarction and Stroke Risk in Young Healthy Men Treated with Injectable Testosterone. Int J Endocrinol, 2015. 2015: p. 970750.
66. Sharma, R., et al., Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J, 2015. 36(40): p. 2706-15.
67. Baillargeon, J., et al., Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy. Mayo Clin Proc, 2015. 90(8): p. 1038-45.
68. Etminan, M., et al., Testosterone therapy and risk of myocardial infarction: a pharmacoepidemiologic study. Pharmacotherapy, 2015. 35(1): p. 72-8.
69. Anderson, J.L., et al., Impact of Testosterone Replacement Therapy on Myocardial Infarction, Stroke, and Death in Men With Low Testosterone Concentrations in an Integrated Health Care System. Am J Cardiol, 2016. 117(5): p. 794-9.
70. Ramasamy, R., et al., Association Between Testosterone Supplementation Therapy and Thrombotic Events in Elderly Men. Urology, 2015. 86(2): p. 283-5.
71. Cheetham, T., et al., Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency. JAMA Internal Medicine, 2017.
72. Corona, G., et al., Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf, 2014. 13(10): p. 1327-51.
73. Corona, G., E. Maseroli, and M. Maggi, Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother, 2014. 15(13): p. 1903-26.
74. Snyder, P.J., et al., Effects of Testosterone Treatment in Older Men. N Engl J Med, 2016. 374(7): p. 611-24.
75. Basaria, S., et al., Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial. JAMA, 2015. 314(6): p. 570-81.
76. Sjöström, L., et al., Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med, 2007. 357(8): p. 741-52.
77. Miras, A.D. and C.W. le Roux, Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery? Int J Obes (Lond), 2014. 38(3): p. 325-33.
78. Look, A.R.G., et al., Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med, 2013. 369(2): p. 145-54.
79. Khera, R., et al., Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA, 2016. 315(22): p. 2424-34.